Format

Send to

Choose Destination
J Rheumatol. 1994 Jul;21(7):1220-3.

A Canadian survey of current methotrexate prescribing practices in rheumatoid arthritis.

Author information

1
Department of Medicine, University of Western Ontario, London, Canada.

Abstract

OBJECTIVE:

To conduct a cross sectional survey of methotrexate (MTX) prescribing practices of Canadian rheumatologists in their treatment of rheumatoid arthritis (RA).

METHODS:

A 15-item questionnaire was mailed to 197 rheumatologists with a 79% response rate after 3 mailings.

RESULTS:

The usual starting dose was 7.5 mg/week (range = 2.5-15.0) and the usual maximum dose prescribed was 15 mg/week (range = 10-50); 81% routinely coadministered MTX and non-steroidal antiinflammatory drugs; 28% routinely used folic acid prophylaxis; 97% of respondents performed regular assessments of liver function. Only 17% requested a liver biopsy after a certain time and 23% after a certain cumulative dose. Sixty-two percent performed pre-MTX liver biopsy on patients with liver function abnormalities. Only 14% of respondents routinely performed pulmonary function tests. Ninety-one percent of respondents noted that 1-50% (mode = 10%) of patients refused to accept MTX therapy after it had been recommended, usually because of fear of side effects.

CONCLUSION:

Despite potential toxicity, the majority of respondents used MTX in the treatment of adult RA.

PMID:
7966061
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center